Gubra A/S (CPH:GUBRA)
Denmark · Delayed Price · Currency is DKK 406.20
-7.40 (-1.79%)
Jul 16, 2025, 4:59 PM CET
Gubra Revenue
In the year 2024, Gubra had annual revenue of 265.74M DKK with 29.63% growth. Gubra had revenue of 145.11M in the half year ending December 31, 2024, with 42.69% growth.
Revenue
265.74M
Revenue Growth
+29.63%
P/S Ratio
24.93
Revenue / Employee
1.02M
Employees
260
Market Cap
6.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 265.74M | 60.74M | 29.63% |
| Dec 31, 2023 | 205.01M | 5.62M | 2.82% |
| Dec 31, 2022 | 199.38M | -55.95M | -21.91% |
| Dec 31, 2021 | 255.33M | 83.03M | 48.19% |
| Dec 31, 2020 | 172.30M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 303.14B |
| Coloplast | 27.79B |
| Genmab | 22.30B |
| Demant | 22.42B |
| ALK-Abelló | 5.71B |
| H. Lundbeck | 22.95B |
| Zealand Pharma | 55.69M |
| Ambu A/S | 5.83B |
Gubra News
- 6 weeks ago - Gubra’s Innovation in Peptide-Based Drug Discovery - Nasdaq
- 4 months ago - Healthy Returns: AbbVie is the newest potential weight loss drug market player - CNBC
- 4 months ago - AbbVie Steps Into The Ring In The Obesity Drug Wars - Seeking Alpha
- 4 months ago - AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race - Benzinga
- 4 months ago - AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal - Investopedia
- 4 months ago - AbbVie (ABBV) Enters Weight Loss Market with $2.2 Billion Gubra Deal - GuruFocus
- 4 months ago - AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. - Investor's Business Daily
- 4 months ago - AbbVie forays into obesity market with up to $2.2B Gubra license deal - Seeking Alpha